Clinical Trials - ArriVent Biopharma

Programs

ArriVent is studying furmonertinib globally in patients with NSCLC with EGFR mutations or HER2 exon 20 insertion mutations. To learn more about these clinical studies, please select from below or visit clinicaltrials.gov.

FURVENT
(FURMO-004)
First-line Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (NCT05607550)
FURTHER
(FURMO-002)
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations (NCT05364073)

For more information about furmonertinib clinical studies:

FURMO@nullarrivent.com